BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23917311)

  • 1. Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.
    Marjuki H; Mishin VP; Sleeman K; Okomo-Adhiambo M; Sheu TG; Guo L; Xu X; Gubareva LV
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5209-15. PubMed ID: 23917311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
    Okomo-Adhiambo M; Sleeman K; Lysén C; Nguyen HT; Xu X; Li Y; Klimov AI; Gubareva LV
    Influenza Other Respir Viruses; 2013 Sep; 7(5):645-58. PubMed ID: 23575174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro neuraminidase inhibitory concentration (IC
    Ikematsu H; Kawai N; Tani N; Chong Y; Bando T; Iwaki N; Kashiwagi S
    J Infect Chemother; 2020 Aug; 26(8):775-779. PubMed ID: 32249161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
    Takashita E; Meijer A; Lackenby A; Gubareva L; Rebelo-de-Andrade H; Besselaar T; Fry A; Gregory V; Leang SK; Huang W; Lo J; Pereyaslov D; Siqueira MM; Wang D; Mak GC; Zhang W; Daniels RS; Hurt AC; Tashiro M
    Antiviral Res; 2015 May; 117():27-38. PubMed ID: 25721488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.
    Sheu TG; Deyde VM; Okomo-Adhiambo M; Garten RJ; Xu X; Bright RA; Butler EN; Wallis TR; Klimov AI; Gubareva LV
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3284-92. PubMed ID: 18625765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low antiviral resistance in Influenza A and B viruses isolated in Mexico from 2010 to 2023.
    Franco-May DA; Gómez-Carballo J; Barrera-Badillo G; Cruz-Ortíz MN; Núñez-García TE; Arellano-Suárez DS; Wong-Arámbula C; López-Martínez I; Wong-Chew RM; Ayora-Talavera G
    Antiviral Res; 2024 Jul; 227():105918. PubMed ID: 38795911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.
    Kossyvakis A; Mentis AA; Tryfinopoulou K; Pogka V; Kalliaropoulos A; Antalis E; Lytras T; Meijer A; Tsiodras S; Karakitsos P; Mentis AF
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):361-371. PubMed ID: 27848039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
    Bauer K; Dürrwald R; Schlegel M; Pfarr K; Topf D; Wiesener N; Dahse HM; Wutzler P; Schmidtke M
    Med Microbiol Immunol; 2012 Feb; 201(1):61-72. PubMed ID: 21688167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological self-sampling to monitor influenza antiviral susceptibility in a community cohort.
    Lackenby A; Elliot AJ; Powers C; Andrews N; Ellis J; Bermingham A; Thompson C; Galiano M; Large S; Durnall H; Fleming D; Smith G; Zambon M
    J Antimicrob Chemother; 2013 Oct; 68(10):2324-31. PubMed ID: 23759670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
    Gubareva LV; Besselaar TG; Daniels RS; Fry A; Gregory V; Huang W; Hurt AC; Jorquera PA; Lackenby A; Leang SK; Lo J; Pereyaslov D; Rebelo-de-Andrade H; Siqueira MM; Takashita E; Odagiri T; Wang D; Zhang W; Meijer A
    Antiviral Res; 2017 Oct; 146():12-20. PubMed ID: 28802866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
    Samson M; Abed Y; Desrochers FM; Hamilton S; Luttick A; Tucker SP; Pryor MJ; Boivin G
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5220-8. PubMed ID: 24957832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States.
    Nguyen HT; Trujillo AA; Sheu TG; Levine M; Mishin VP; Shaw M; Ades EW; Klimov AI; Fry AM; Gubareva LV
    Antiviral Res; 2012 Mar; 93(3):381-6. PubMed ID: 22330888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.
    Mishin VP; Sleeman K; Levine M; Carney PJ; Stevens J; Gubareva LV
    Antiviral Res; 2014 Jan; 101():93-6. PubMed ID: 24239666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic and genetic characterization of influenza viruses isolated in Mozambique during the 2015 season.
    Tivane A; Daniels R; Nguenha N; Machalele L; Nacoto A; Pale M; Mateonane E; Mavale S; Chilundo J; Muteto D; Salência J; Albati F; Gudo E; Mussá T; McCauley J
    PLoS One; 2018; 13(7):e0201248. PubMed ID: 30048502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis.
    Duan S; Boltz DA; Li J; Oshansky CM; Marjuki H; Barman S; Webby RJ; Webster RG; Govorkova EA
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4718-27. PubMed ID: 21730113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay.
    Nakauchi M; Ujike M; Obuchi M; Takashita E; Takayama I; Ejima M; Oba K; Konomi N; Odagiri T; Tashiro M; Kageyama T;
    J Med Virol; 2011 Jul; 83(7):1121-7. PubMed ID: 21567417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
    Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
    J Med Virol; 2015 Jan; 87(1):45-56. PubMed ID: 25042157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.